Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Audiology & Neuro-Otology|May 20, 2009
Acute cochlear nucleus compression alters tuning properties of inferior colliculus neuronsKatherine N Crea, Mohit N Shivdasani, Rebecca E Argent, et al.Journal of Neural Engineering|August 10, 2013
Suprachoroidal electrical stimulation: effects of stimulus pulse parameters on visual cortical responsesSam E John, Mohit N Shivdasani, Chris E Williams, et al.Journal of Neural Engineering|May 19, 2012
Visual cortex responses to suprachoroidal electrical stimulation of the retina: effects of electrode return configurationRosemary Cicione, Mohit N Shivdasani, James B Fallon, et al.Journal of Neural Engineering|April 16, 2011
An automated system for rapid evaluation of high-density electrode arrays in neural prosthesesSam E John, Mohit N Shivdasani, James Leuenberger, et al.The Journal of Pharmacology and Experimental Therapeutics|November 1, 1996
Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complexL J Bristow, P H Hutson, J J Kulagowski, et al.Journal of Medicinal Chemistry|August 1, 1997
5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptorJ L Castro, H B Broughton, M G Russell, et al.Journal of Neural Engineering|May 24, 2022
Preclinical safety study of a fully implantable, sub-scalp ring electrode array for long-term EEG recordingsYuri Benovitski, Alan Lai, Alexia Saunders, et al.Journal of Medicinal Chemistry|March 3, 1999
3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agentsM S Chambers, L J Street, S Goodacre, et al.Journal of Medicinal Chemistry|February 16, 1996
Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureasJ L Castro, R G Ball, H B Broughton, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcomaMark A Dickson, William D Tap, Mary Louise Keohan, et al.Pageof 3